BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Balakumar P, Sambathkumar R, Mahadevan N, Muhsinah AB, Alsayari A, Venkateswaramurthy N, Dhanaraj SA. Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits. Pharmacological Research 2019;144:132-41. [DOI: 10.1016/j.phrs.2019.03.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Ma X, Su M, He Q, Zhang Z, Zhang F, Liu Z, Sun L, Weng J, Xu S. PHACTR1, a coronary artery disease risk gene, mediates endothelial dysfunction. Front Immunol 2022;13:958677. [DOI: 10.3389/fimmu.2022.958677] [Reference Citation Analysis]
2 Lin Y, Liu R, Huang Y, Yang Z, Xian J, Huang J, Qiu Z, Lin X, Zhang M, Chen H, Wang H, Huang J, Xu G. Reactivation of PPARα alleviates myocardial lipid accumulation and cardiac dysfunction by improving fatty acid β-oxidation in Dsg2-deficient arrhythmogenic cardiomyopathy. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.05.018] [Reference Citation Analysis]
3 Yamamoto T, Sano M. Deranged Myocardial Fatty Acid Metabolism in Heart Failure. Int J Mol Sci 2022;23:996. [PMID: 35055179 DOI: 10.3390/ijms23020996] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
4 Li M, Qi L, Li Y, Zhang S, Lin L, Zhou L, Han W, Qu X, Cai J, Ye M, Shi K. Association of Pericardiac Adipose Tissue With Coronary Artery Disease. Front Endocrinol (Lausanne) 2021;12:724859. [PMID: 34552562 DOI: 10.3389/fendo.2021.724859] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Li Z, Lu S, Li X. The role of metabolic reprogramming in tubular epithelial cells during the progression of acute kidney injury. Cell Mol Life Sci 2021;78:5731-41. [PMID: 34185125 DOI: 10.1007/s00018-021-03892-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gulati N, Kumar Chellappan D, Tambuwala M, A A Aljabali A, Prasher P, Kumar Singh S, Anand K, Sharma A, Kumar Jha N, Gupta G, Dua K, Dureja H. Oral Nanoemulsion of Fenofibrate: Formulation, Characterization, and In Vitro Drug Release Studies. Assay Drug Dev Technol 2021;19:246-61. [PMID: 33989048 DOI: 10.1089/adt.2021.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 López B, Ravassa S, Moreno MU, José GS, Beaumont J, González A, Díez J. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nat Rev Cardiol 2021;18:479-98. [PMID: 33568808 DOI: 10.1038/s41569-020-00504-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
8 Cortes-Lopez F, Sanchez-Mendoza A, Centurion D, Cervantes-Perez LG, Castrejon-Tellez V, Del Valle-Mondragon L, Soria-Castro E, Ramirez V, Sanchez-Lopez A, Pastelin-Hernandez G, Garcia-Niño WR, Sanchez-Aguilar M, Ibarra-Lara L. Fenofibrate Protects Cardiomyocytes from Hypoxia/Reperfusion- and High Glucose-Induced Detrimental Effects. PPAR Res 2021;2021:8895376. [PMID: 33505452 DOI: 10.1155/2021/8895376] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Liu J, Qu J, Chen H, Ge P, Jiang Y, Xu C, Chen H, Shang D, Zhang G. The pathogenesis of renal injury in obstructive jaundice: A review of underlying mechanisms, inducible agents and therapeutic strategies. Pharmacol Res 2021;163:105311. [PMID: 33246170 DOI: 10.1016/j.phrs.2020.105311] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
10 Balakumar P, Alqahtani A, Khan NA, Mahadevan N, Dhanaraj SA. Mechanistic insights into hyperuricemia-associated renal abnormalities with special emphasis on epithelial-to-mesenchymal transition: Pathologic implications and putative pharmacologic targets. Pharmacological Research 2020;161:105209. [DOI: 10.1016/j.phrs.2020.105209] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
11 Rogosnitzky M, Berkowitz E, Jadad AR. No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19. JMIRx Med 2020;1:e19583. [PMID: 33724265 DOI: 10.2196/19583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Balakumar P, Sambathkumar R, Mahadevan N, Muhsinah AB, Alsayari A, Venkateswaramurthy N, Jagadeesh G. A potential role of the renin-angiotensin-aldosterone system in epithelial-to-mesenchymal transition-induced renal abnormalities: Mechanisms and therapeutic implications. Pharmacol Res 2019;146:104314. [PMID: 31229564 DOI: 10.1016/j.phrs.2019.104314] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]